Eaton Vance Management’s CRISPR Therapeutics CRSP Stock Holding History

Eaton Vance Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.33M	Hold	20,413	–	–	﹤0.01%	1163
2022 Q2	$1.24M	Sell	20,413 -1,180	-5%	-$69.4K	﹤0.01%	1209
2022 Q1	$1.35M	Sell	21,593 -70	-0.3%	-$4.39K	﹤0.01%	1295
2021 Q4	$1.64M	Buy	21,663 +70	+0.3%	+$6.12K	﹤0.01%	1066
2021 Q3	$2.29M	Buy	21,593 +180	+0.8%	+$22.6K	﹤0.01%	904
2021 Q2	$3.47M	Buy	21,413 +1,000	+5%	+$122K	﹤0.01%	876
2021 Q1	$2.49M	Hold	20,413	–	–	﹤0.01%	924
2020 Q4	$3.13M	Hold	20,413	–	–	﹤0.01%	828
2020 Q3	$1.71M	Hold	20,413	–	–	﹤0.01%	871
2020 Q2	$1.5M	Hold	20,413	–	–	﹤0.01%	874
2020 Q1	$866K	Hold	20,413	–	–	﹤0.01%	945
2019 Q4	$1.24M	Hold	20,413	–	–	﹤0.01%	926
2019 Q3	$837K	Hold	20,413	–	–	﹤0.01%	1013
2019 Q2	$961K	Hold	20,413	–	–	﹤0.01%	964
2019 Q1	$729K	Hold	20,413	–	–	﹤0.01%	991
2018 Q4	$583K	Hold	20,413	–	–	﹤0.01%	969
2018 Q3	$905K	Hold	20,413	–	–	﹤0.01%	935
2018 Q2	$1.2M	Buy	+20,413	New	+$1.16M	﹤0.01%	848

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eaton Vance Management's CRSP Position: Q3 2022 in Review

Eaton Vance Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2022 at 20,413 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Eaton Vance Management first reported a position in CRSP in Q2 2018 and has held it in 18 quarters since. The position peaked at $3.47M in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Eaton Vance Management held 20,413 shares of CRISPR Therapeutics worth $1.33M as of Q3 2022.
Eaton Vance Management left its CRISPR Therapeutics share count unchanged in Q3 2022.
CRISPR Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1163 holding.
Eaton Vance Management first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 18 quarters since.
Eaton Vance Management's CRISPR Therapeutics position peaked at $3.47M in Q2 2021.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.